HILLEVAX
HilleVax is a biopharmaceutical company that focuses on the development and commercialization of novel vaccines. HilleVax was founded in 2021 and was headquartered in Boston, Massachusetts.
HILLEVAX
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2021-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.hillevax.com
Total Employee:
11+
Status:
Active
Contact:
(617) 213-5054
Email Addresses:
[email protected]
Total Funding:
135 M USD
Technology used in webpage:
Wordpress Plugins Sitelinks Search Box Microsoft Azure DNS Google Analytics 4 Page Links To Adobe Marketing Cloud Adobe Audience Manager JobVite
Similar Organizations
Adcentrx Therapeutics
Adcentrx is a biotechnology company focused on therapeutic development for cancer and other life-threatening diseases
Akeso Biopharma
Akeso Biopharma is a biopharmaceutical company committed to the discovery, development, and commercialization of therapies.
AmVac
AmVac is a biopharmaceutical company focusing on the development and commercialization of immune therapies and prophylactic vaccines.
Animal Bioscience
Animal Bioscience is a pet platform.
Captura Biopharma
Captura Biopharma is an emerging biotechnology company engaged in the development and commercialization of heavy metal chelators.
Day One Biopharmaceuticals
Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Emalex Biosciences, Inc.
Emalex Biosciences is a biopharmaceutical company dedicated to the development of new and novel treatments.
Entera Bio
Entera Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel drug delivery platform.
Equilibre
Equilibre is a biopharmaceuticals corporation developing differentiated and novel therapeutic candidates.
Mirum Pharmaceuticals
Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
PeptiVir
PeptiVir, Inc., a biopharmaceutical company, engages in the development and commercialization of synthetic peptide-based vaccines for the
PhytoChem Pharmaceuticals
PhytoChem is a pharmaceutical company focused on the research, development, and commercialization of novel compounds.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
resTORbio
resTORbio is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics.
Stealth BioTherapeutics
Stealth BioTherapeutics is a clinical-stage biotechnology company focused on genetic diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Deerfield
Deerfield investment in Venture Round - HilleVax
Abingworth
Abingworth investment in Venture Round - HilleVax
Greenspring Associates
Greenspring Associates investment in Venture Round - HilleVax
RA Capital Management
RA Capital Management investment in Venture Round - HilleVax
Catalys Pacific
Catalys Pacific investment in Venture Round - HilleVax
Richard King Mellon Foundation
Richard King Mellon Foundation investment in Venture Round - HilleVax
Qiming Venture Partners USA
Qiming Venture Partners USA investment in Venture Round - HilleVax
Perceptive Advisors
Perceptive Advisors investment in Venture Round - HilleVax
BVF Partners
BVF Partners investment in Venture Round - HilleVax
Lightspeed Venture Partners
Lightspeed Venture Partners investment in Venture Round - HilleVax
Official Site Inspections
http://www.hillevax.com Semrush global rank: 4.57 M Semrush visits lastest month: 2.27 K
- Host name: 23.185.0.1
- IP address: 23.185.0.1
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "HilleVax"
Hillevax - Advancing a Vaccine to Protect Against …
Norovirus is estimated to cause approximately 700 million cases of gastroenteritis and 200,000 deaths worldwide annually. $ 60 B+See details»
HilleVax - Crunchbase Company Profile & Funding
Additionally, HilleVax has entered into an exclusive license agreement to acquire norovirus vaccine rights, suggesting an expansion of its product portfolio and …See details»
HilleVax, Inc. (HLVX) Company Profile & Facts - Yahoo Finance
HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts. Corporate Governance HilleVax, Inc.’s ISS Governance QualityScore as of May 1, 2025 is 9.See details»
HilleVax - LinkedIn
HilleVax is a biopharmaceutical company focused on the development and commercialization of novel vaccines. Our initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in ...See details»
HilleVax - Contacts, Employees, Board Members, Advisors & Alumni
HilleVax is a biopharmaceutical company that focuses on the development and commercialization of novel vaccines. ... Experience the new Crunchbase, powered by AI . Experience the new …See details»
HilleVax (HLVX) Company Profile & Description - Stock Analysis
Apr 29, 2022 HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company develops HIL-214, a …See details»
HilleVax, Inc. Company Profile | Boston, MA - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for HilleVax, Inc. of Boston, MA. Get the latest business insights from Dun & Bradstreet.See details»
HilleVax Company Profile - Office Locations, Competitors ... - Craft
HilleVax is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. Its initial program, HIL-214, is a virus-like particle (VLP) …See details»
HilleVax Overview | SignalHire Company Profile
HilleVax is a biopharmaceutical company that focuses on the development and commercialization of novel vaccines.\n\n\nHilleVax was founded in 2021 and was headquartered in Boston, ...See details»
Pipeline - HilleVax
Norovirus. Norovirus is the most common cause of viral acute gastroenteritis (AGE) worldwide 2 and is characterized by symptoms, including diarrhea, vomiting, abdominal pain, nausea, and fever, that may lead to clinically …See details»
20 Things You Didn’t Know about HilleVax Inc - Money Inc
Dec 7, 2022 Hillevax Inc is a pharmaceutical company that caught the eye of investors with its recent IPO. It’s an American startup headquartered in Boston, Massachusetts, It’s a solid and …See details»
Mission, Vision & Core Values of HilleVax
Dec 19, 2024 Driving Innovation Through Core Values. At HilleVax, we believe that driving innovation is at the core of our mission. Our commitment to developing and commercializing …See details»
HilleVax - Funding, Financials, Valuation & Investors - Crunchbase
HilleVax is registered under the ticker NASDAQ:HLVX . Their stock opened with $17.00 in its Apr 29, 2022 IPO. Stock Symbol NASDAQ:HLVX ; Valuation at IPO $538.3M; Money Raised at …See details»
HilleVax, Inc. Reports Q1 2025 Financial Results and Evaluates
5 days ago HilleVax, Inc. announced its financial results for the first quarter of 2025, reporting a total of $159.5 million in cash, cash equivalents, and marketable securities, down from $171.4 …See details»
HilleVax to Present at Upcoming Investor Conferences
BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, …See details»
HilleVax - Abingworth LLP
HilleVax is a biopharmaceutical company focused on the development and commercialisation of novel vaccine candidates. Its initial programme, HIL-214, is a virus-like particle (VLP) based …See details»
HilleVax, Inc. (HLVX)
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company develops HIL-214, a virus …See details»
HilleVax Reports First Quarter 2025 Financial Results and …
Mar 31, 2025 HilleVax is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. Its initial programs, HIL-214 and HIL-216, are virus-like …See details»
Takeda and Frazier Healthcare Partners Announce ... - HilleVax
Jul 27, 2021 to partner again with Takeda to form HilleVax,” said Tachi Yamada, M.D., co-founder of HilleVax and Venture Partner with Frazier. “Norovirus causes significant morbidity …See details»
HilleVax: Revenue, Worth, Valuation & Competitors 2025
HilleVax is a Biotech related company with 47 employees an estimated revenue of $17.2M, and. It has 10 competitors including Dermavant Sciences , Metrum Research Group and Clovis …See details»